Search

AYALA'S EX-BMS DRUG SHOWS PROMISE IN TRIPLE-NEGATIVE BREAST CANCER

Israeli biotech Ayala Pharmaceuticals has just added $30 million in a Novartis-backed series B round. As preclinical results have shown,...

Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More

BIO ROUNDUP: OPIOIDS IN COURT, IPO PARADE, BRAIN CANCER BET & MORE

Pharmaceutical companies that make or market opioids have found themselves in legal hot water, and much of the heat is coming from...

 
 
 

NOVARTIS' KYMRIAH HEAD JUMPS SHIP TO T-CELL BIOTECH ATARA AS ITS R&D CHIEF QUITS

Novartis has lost its head of oncology and lead for its global head, cell and gene therapy unit Pascal Touchon as he steps up to become...

AVEXIS RECEIVES FDA APPROVAL FOR ZOLGENSMA, FIRST AND ONLY GENE THERAPY FOR PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY

Posted on: 25 May 2019, AveXis, a Novartis company, today announced the US Food and Drug Administration has approved Zolgensma® for...

 
 
 
CMS delays national coverage determination for CAR-T therapies

CMS DELAYS NATIONAL COVERAGE DETERMINATION FOR CAR-T THERAPIES

In a statement, the agency said that a decision on whether to have Medicare cover the cell therapies would not be issued Friday, but...

 
 
 
 
 
 

POSEIDA TO ADVANCE CAR-T FOR MYELOMA WITH NOVARTIS-LED $142M ROUND

The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with...

 
 
 
Bio Roundup: Nationwide's Rise, a Surgeon's Quest, CRISPR USA & More

BIO ROUNDUP: NATIONWIDE'S RISE, A SURGEON'S QUEST, CRISPR USA & MORE

Persistence and perseverance were the themes of two of our top stories this week. First there's the story of Nationwide Children's...

 
 
 
How an Ohio Kids' Hospital Quietly Became Ground Zero for Gene Therapy

HOW AN OHIO KIDS' HOSPITAL QUIETLY BECAME GROUND ZERO FOR GENE THERAPY

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America's other...

 
 
 

NOVARTIS JUST SIGNED A $1.6B BUYOUT PACT WITH A LEAD PLAYER IN AN EMERGING ANTI-INFLAMMATORY FIELD

The executive crew at IFM has just racked up their second blockbuster-sized biotech sale in less than two years. Not long after Bristol-Myers...

Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre

NOVARTIS ADDS INFLAMMATION DRUGS TO PIPELINE WITH DEAL FOR IFM TRE

Less than a year after launching and only days after advancing its lead program into clinical trials, drug developer IFM Tre is in...

 
 
 
Bio Roundup: Golumbeski's Legacy, CRISPR Moratorium, Rebate Week & More

BIO ROUNDUP: GOLUMBESKI'S LEGACY, CRISPR MORATORIUM, REBATE WEEK & MORE

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb's proposal to buy Celgene for $74 billion...

 
 
 
Clinical Analytics Platform TriNetX Raises $40M to Speed Drug Trials

CLINICAL ANALYTICS PLATFORM TRINETX RAISES $40M TO SPEED DRUG TRIALS

TriNetX, a Cambridge, MA developer of data analytics software for clinical research, has raised $40 million in a Series D funding round...

The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski

THE LIFE, TROUBLES, AND CELGENE LEGACY OF DEAL GURU GEORGE GOLUMBESKI

George Golumbeski is one of the most prolific dealmakers in the biopharmaceutical world. But the deal that changed his life is a pact...